direkt zum Inhalt springen

direkt zum Hauptnavigationsmenü

Sie sind hier

TU Berlin

Page Content

Health Economics


  • Kuklinski D, Vogel J, Geissler A (2021): The impact of quality in hospital choice. Which information affects patients' behavior for colorectal resection or knee replacement? [1]


  • Waitzberg R, Quentin W, Daniels E, Paldi Y, Busse R, Greenberg D (2020): Effects of Activity-Based Hospital Payments in Israel: A Qualitative Evaluation Focusing on the Perspectives of Hospital Managers and Physicians. [2]
  • Quentin W, Busse R, Vogt V, Czihal T, Offermanns M, Grobe T, Focke K (2020): Entwicklungen eines Systems zur Klassifikation des morbiditätsbezogenen Versorgungsbedarfs (PopGroup). [3]
  • Brammli-Greenberg S, Waitzberg R (2020): Integrating public and private insurance in the Israeli health system: an attempt to reconcile conflicting values. [4]
  • van Ginneken E, Waitzberg R, Barnes A, Quntin W, Smatana M, Rice T (2020): Achieving Person-Centred Health Systems: Evidence, Strategies and Challenges. [5]


  • Waitzberg R, Quentin W, Daniels E, Perman V, Brammli-Greenberg S, Busse R, Greenberg D (2019): The 2010 expansion of activity-based hospital payment in Israel: an evaluation of effects at the ward level [6]
  • Hsiao A, Vogt V, Quentin W (2019): Effect of corruption on perceived difficulties in healthcare access in sub-Saharan Africa. [7]
  • Brammli-Greenberg S, Glazer J, Waitzberg R (2019): Modest risk-sharing significantly reduces health plans’ incentives for service distortion. [8]


  • Ex P, Felgner S, Henschke C (2018): Rechtsprechungen zur Kostenerstattung von neuen Gesundheitstechnologien in der GKV: Eine systematische Übersicht. [9]
  • Hsiao A, Hall HA, Mogasale V, Quentin W (2018): The health economics of cholera: A systematic review [10]


  • Struckmann V, Quentin W, Busse R, van Ginneken E (2017): How to strengthen financing mechanisms to promote care for people with multimorbidity in Europe? [11]


  • Ekman I, Busse R, van Ginneken E, van Hoof C, van Ittersum L, Klink A, Kremer JA, Miraldo M, Olauson A, de Raedt W, Rosen-Zvi M, Strammiello V, Törnell J, Swedberg K (2016): Health-care improvements in a financially constrained environment. [12]
  • van Ginneken E (2016): Governing competitive insurance market reform: case studies from the Netherlands and Switzerland [13]


  • Busse R, Blümel M (2015): Payment systems to improve quality, efficiency, and care coordination for chronically ill patients - a framework and country examples. In: Mas N, Wisbaum W (eds.) The triple aim for the future of health care. Madrid: Funcas [14]
  • Panteli D, Eckhardt H, Nolting A, Busse R, Kulig M (2015): From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries. Health Research Policy and Systems [15]
  • Pimperl A, Schreyögg J, Rothgang H, Busse R, Glaeske G, Hildebrandt H: Ökonomische Erfolgsmessung von integrierten Versorgungsstrukturen – Gütekriterien, Herausforderungen, Best-Practice-Modell. Das Gesundheits­wesen (DOI 10.1055/s-0034-1381988) [16]


  • Busse R, Blümel M (2014): Sistemas de pago para mejorar la calidad, eficiencia y coordinación de la atención a los pacientes crónicos. Un marco y ejemplos nacionales. Papeles de Economía Española; 142: 50-61 [17]
  • Van der Wees PJ, Nijhuis-van der Sanden MW, van Ginneken E, Ayanian JZ, Schneider EC, Westert GP (2014): Governing healthcare through performance measurement in Massachusetts and the Netherlands. Health Policy. 2014 May;116(1):18-26. [18]
  • Vuong DA, Flessa S, Marshall P, Luong KN, Ha ST, Busse R (2014): Determining the impacts of hospital cost-sharing on the uninsured near-poor households in Vietnam. International Journal for Equity in Health 13: 40 [19]


  • Busse R , Schreyögg J, Stargardt T (Hrsg.) (2013): Management im Gesundheitswesen. Das Lehrbuch für Studium und Praxis. 3., vollständig überarbeitete und erweiterte Auflage. Berlin-Heidelberg: Springer [20]
  • Ismail F, Busse R (2013): Die Herausforderungen für gesetzliche Krankenkassen bei der Steuerung der Versorgung von Hochkostenfällen. In: Burger S (Hrsg.) Alter und Multimorbidität. Berlin: medhochzwei, S. 447-463 [21]
  • McKee M, Busse R (2013): Medical savings accounts: Singapore’s non-solution to healthcare costs. BMJ 347: f4797 [22]
  • Stabile M, Thomson S, Allin S, Boyle S, Busse R, Chevreul K, Marchildon G, Mossialos E (2013): Health Care Cost Containment Strategies Used In Four Other High-Income Countries Hold Lessons For The United States. Health Affairs 32(4): 643-652 [23]



  • Schreyögg J (2008): A micro-costing approach to estimating hospital costs for appendectomy in a Cross-European. Health Economics 17(S1): S59-S69 [24]
  • Schreyögg J, Tiemann O, Stargardt T, Busse R (2008): Cross-country comparisons of costs: the use of episode-specific transitive purchasing power parities with standardised cost categories. Health Economics 17(S1): S95-S103 [25]
  • Stargardt T (2008): Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries. Health Economics 17(S1): S9-S20 [26]
  • Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA (2008): Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ; 11: 89-97. [27]
  • Tiemann O (2008): Variations in hospitalisation costs for acute myocardial infarction - a comparison across Europe. Health Economics 17(S1): S33-S45 [28]


  • Busse R (2006): Health economics. Objectives, methodology, relevance - Gesundheitsschutz 49(1): 3-10 [29]
  • Auerbach H, Schreyögg J, Busse R (2006): Cost-effectiveness Analysis of Telemedical Devices for Pre-clinical Traffic Accident Emergency Rescue in Germany. Technology and Health Care 14(3): 189-197 [30]
  • Grabka M, Schreyögg J, Busse R(2006):The impact of co-payments on patient behavior: evidence from a natural experiment [31]
  • Schreyögg J, Hollmeyer H, Staab D, Bluemel M, Busse R (2006): Hospitalization costs of cystic fibrosis – identifying homogenous cost-groups and determining predictors for cost variation. Pharmacoeconomics 24(10): 999-1009 [32]
  • What makes the difference? Analysing methodologies to determine DRGs in nine European countries [33]
  • Schreyögg J, Tiemann O, Busse R (2006): Cost accounting to determine prices: how well do prices reflect costs in the German DRG-system? Health Care Management Science 9(3): 269-279 [34]


  • Krauth C, Jalivand N, Welte T, Busse R (2003): Cystic Fibrosis: Cost of illness and considerations for the economic evaluation of potential therapies. Pharmaco­economics 21(14): 1001-1024 [35]

To top

------ Links: ------

Zusatzinformationen / Extras

Quick Access:

Schnellnavigation zur Seite über Nummerneingabe

Auxiliary Functions

Copyright TU Berlin 2008